- Home
- FFWM vs ALT Comparison
FFWM vs ALT Comparison
Compare FFWM & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFWM | ALT |
|---|---|---|
| Founded | 1990 | 1997 |
| Country | United States | United States |
| Employees | 485 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 518.9M | 415.3M |
| IPO Year | 2014 | 2005 |
Fundamental Metrics
Financial Performance| Metric | FFWM | ALT |
|---|---|---|
| Price | $5.56 | $3.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.17 | ★ $17.67 |
| AVG Volume (30 Days) | 670.0K | ★ 2.9M |
| Earning Date | 04-29-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,373,000.00 | $41,000.00 |
| Revenue This Year | $56.34 | N/A |
| Revenue Next Year | $10.68 | $756,308.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $4.42 | $2.91 |
| 52 Week High | $6.72 | $7.73 |
Technical Indicators
Market Signals| Indicator | FFWM | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 36.22 | 32.86 |
| Support Level | $5.44 | $2.91 |
| Resistance Level | $5.61 | $4.25 |
| Average True Range (ATR) | 0.20 | 0.23 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 15.93 | 1.80 |
Price Performance
Historical ComparisonAbout FFWM First Foundation Inc.
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.